179 related articles for article (PubMed ID: 8601956)
1. Cost-effectiveness of the transdermal nicotine patch as an adjunct to physicians' smoking cessation counseling.
Fiscella K; Franks P
JAMA; 1996 Apr; 275(16):1247-51. PubMed ID: 8601956
[TBL] [Abstract][Full Text] [Related]
2. The cost-effectiveness of the nicotine transdermal patch for smoking cessation.
Wasley MA; McNagny SE; Phillips VL; Ahluwalia JS
Prev Med; 1997; 26(2):264-70. PubMed ID: 9085397
[TBL] [Abstract][Full Text] [Related]
3. Cost-effectiveness of the clinical practice recommendations in the AHCPR guideline for smoking cessation. Agency for Health Care Policy and Research.
Cromwell J; Bartosch WJ; Fiore MC; Hasselblad V; Baker T
JAMA; 1997 Dec; 278(21):1759-66. PubMed ID: 9388153
[TBL] [Abstract][Full Text] [Related]
4. Cost-effectiveness of face-to-face smoking cessation interventions: a dynamic modeling study.
Feenstra TL; Hamberg-van Reenen HH; Hoogenveen RT; Rutten-van Mölken MP
Value Health; 2005; 8(3):178-90. PubMed ID: 15877590
[TBL] [Abstract][Full Text] [Related]
5. Cost-effectiveness of pharmacotherapies for nicotine dependence in primary care settings: a multinational comparison.
Cornuz J; Gilbert A; Pinget C; McDonald P; Slama K; Salto E; Paccaud F
Tob Control; 2006 Jun; 15(3):152-9. PubMed ID: 16728744
[TBL] [Abstract][Full Text] [Related]
6. Varying nicotine patch dose and type of smoking cessation counseling.
Jorenby DE; Smith SS; Fiore MC; Hurt RD; Offord KP; Croghan IT; Hays JT; Lewis SF; Baker TB
JAMA; 1995 Nov; 274(17):1347-52. PubMed ID: 7563558
[TBL] [Abstract][Full Text] [Related]
7. Cost-effectiveness analysis of the first-line therapies for nicotine dependence.
Cornuz J; Pinget C; Gilbert A; Paccaud F
Eur J Clin Pharmacol; 2003 Jul; 59(3):201-6. PubMed ID: 12759795
[TBL] [Abstract][Full Text] [Related]
8. Cost-effectiveness analysis of smoking-cessation counseling training for physicians and pharmacists.
Cantor SB; Deshmukh AA; Luca NS; Nogueras-González GM; Rajan T; Prokhorov AV
Addict Behav; 2015 Jun; 45():79-86. PubMed ID: 25644592
[TBL] [Abstract][Full Text] [Related]
9. Prescription of transdermal nicotine patches for smoking cessation in general practice: evaluation of cost-effectiveness.
Stapleton JA; Lowin A; Russell MA
Lancet; 1999 Jul; 354(9174):210-5. PubMed ID: 10421303
[TBL] [Abstract][Full Text] [Related]
10. Cost-effectiveness of the nicotine patch.
Stevermer J
J Fam Pract; 1996 Aug; 43(2):125-6. PubMed ID: 8708620
[No Abstract] [Full Text] [Related]
11. Cost-effectiveness of pharmacological interventions for smoking cessation: a literature review and a decision analytic analysis.
Song F; Raftery J; Aveyard P; Hyde C; Barton P; Woolacott N
Med Decis Making; 2002; 22(5 Suppl):S26-37. PubMed ID: 12369228
[TBL] [Abstract][Full Text] [Related]
12. Cost-effectiveness analysis of a European primary-care physician training in smoking cessation counseling.
Pinget C; Martin E; Wasserfallen JB; Humair JP; Cornuz J
Eur J Cardiovasc Prev Rehabil; 2007 Jun; 14(3):451-5. PubMed ID: 17568248
[TBL] [Abstract][Full Text] [Related]
13. Nicotine patch therapy for smoking cessation combined with physician advice and nurse follow-up. One-year outcome and percentage of nicotine replacement.
Hurt RD; Dale LC; Fredrickson PA; Caldwell CC; Lee GA; Offord KP; Lauger GG; Marŭsić Z; Neese LW; Lundberg TG
JAMA; 1994 Feb; 271(8):595-600. PubMed ID: 8301791
[TBL] [Abstract][Full Text] [Related]
14. The cost utility of bupropion in smoking cessation health programs: simulation model results for Sweden.
Bolin K; Lindgren B; Willers S
Chest; 2006 Mar; 129(3):651-60. PubMed ID: 16537864
[TBL] [Abstract][Full Text] [Related]
15. Cost-benefit analysis of sustained-release bupropion, nicotine patch, or both for smoking cessation.
Nielsen K; Fiore MC
Prev Med; 2000 Mar; 30(3):209-16. PubMed ID: 10684744
[TBL] [Abstract][Full Text] [Related]
16. Smoking cessation in a blue-collar population: results from an evidence-based pilot program.
Ringen K; Anderson N; McAfee T; Zbikowski SM; Fales D
Am J Ind Med; 2002 Nov; 42(5):367-77. PubMed ID: 12382249
[TBL] [Abstract][Full Text] [Related]
17. Economic evaluation of a telephone- and face-to-face-delivered counseling intervention for smoking cessation in patients with coronary heart disease.
Berndt N; Bolman C; Lechner L; Max W; Mudde A; de Vries H; Evers S
Eur J Health Econ; 2016 Apr; 17(3):269-85. PubMed ID: 25796578
[TBL] [Abstract][Full Text] [Related]
18. Cost-effective primary care-based strategies to improve smoking cessation: more value for money.
Salize HJ; Merkel S; Reinhard I; Twardella D; Mann K; Brenner H
Arch Intern Med; 2009 Feb; 169(3):230-5; discussion 235-6. PubMed ID: 19204212
[TBL] [Abstract][Full Text] [Related]
19. The cost effectiveness of pharmacological smoking cessation therapies in developing countries: a case study in the Seychelles.
Gilbert AR; Pinget C; Bovet P; Cornuz J; Shamlaye C; Paccaud F
Tob Control; 2004 Jun; 13(2):190-5. PubMed ID: 15175539
[TBL] [Abstract][Full Text] [Related]
20. Use and effectiveness of transdermal nicotine in primary care settings.
Cummings KM; Biernbaum RM; Zevon MA; Deloughry T; Jaén CR
Arch Fam Med; 1994 Aug; 3(8):682-9. PubMed ID: 7952254
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
